DDInter1553 DDInter927
Initially approved by the FDA in 1997, quetiapine is a second-generation atypical antipsychotic used in schizophrenia, major depression, and bipolar disorder. Quetiapine demonstrates a high level of therapeutic efficacy and low risk of adverse effects during long-term treatment. It is well-tolerated and a suitable option for some patients with high sensitivity to other drugs, such as [clozapine] and [olanzapine].
Inotuzumab ozogamicin is an antibody-drug conjugate using linker and cytotoxic drug technology similar to that developed for the ground-breaking treatment Mylotarg (), which was approved by the US FDA in 2000 for the treatment of acute myeloid leukaemia. Inotuzumab ozogamicin consists of a recombinant humanised IgG4 kappa CD22-targeting monoclonal antibody covalently attached to calicheamicin derivative, N-acetyl-gamma-calicheamicin dimethylhydrazide, which is a potent DNA-binding cytotoxic agent . Developed by Pfizer and UCB, inotuzumab ozogamicin was granted approval by EU in June 2017 followed by FDA on August 17th, 2017 for the treatment of adults with relapsed or refractory B-cell precursor acute lymphoblastic leukemia (ALL). ALL is a rapidly progressing cancer of the bone marrow that is associated with high mortality rates and low therapeutic response from standard chemotherapies in relasping conditions. In a randomized trial, inotuzumab ozogamicin displayed higher percentages of patients undergoing longer periods of complete remission with no evidence of disease in comparison to patients receiving alternative chemotherapy .
Quetiapine {u} (Compound) resembles {v} (Compound) Trazodone
Quetiapine {u} (Compound) binds {v} (Gene) DRD5
Quetiapine {u} (Compound) upregulates {v} (Gene) SLC11A2
Quetiapine {u} (Compound) palliates {v} (Disease) autistic disorder
Quetiapine {u} (Compound) downregulates {v} (Gene) TM9SF2
Quetiapine {u} (Compound) causes {v} (Side Effect) Salivary hypersecretion
Quetiapine {u} may cause a minor interaction that can limit clinical effects when taken with {v} Metronidazole
Quetiapine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Sitagliptin
Quetiapine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Diphenhydramine
Quetiapine {u} may lead to a major life threatening interaction when taken with {v} Clarithromycin
Quetiapine (Compound) resembles Trazodone (Compound)
Quetiapine (Compound) binds DRD5 (Gene)
Quetiapine (Compound) upregulates SLC11A2 (Gene)
Quetiapine (Compound) palliates autistic disorder (Disease)
Quetiapine (Compound) downregulates TM9SF2 (Gene)
Quetiapine (Compound) causes Salivary hypersecretion (Side Effect)
Quetiapine may cause a minor interaction that can limit clinical effects when taken with Metronidazole
Quetiapine may cause a moderate interaction that could exacerbate diseases when taken with Sitagliptin
Quetiapine may cause a moderate interaction that could exacerbate diseases when taken with Diphenhydramine
Quetiapine may lead to a major life threatening interaction when taken with Clarithromycin